GLP-1 OZEMPIC 2030
Weight-loss drugs like Ozempic: 100 million people on them.
Key figures
People on Ozempic, Wegovy, Mounjaro, Zepbound or their generic copies by 2030: 100 million worldwide, 50 million in the US, 30 million in India and China on $15-a-month copies, 20 million across Europe, Brazil, Japan and the Gulf.
Overweight or obese adults worldwide: 2 billion when I called it in 2021, 2.5 billion in 2025, 3 billion by 2030, and the US adult obesity rate 40.3% (CDC, measured 2021 to 2023), 30% by 2030, the first fall in 50 years.
Countries where public health insurance pays for Ozempic-class weight-loss drugs by 2030: 20, up from a handful today (US, UK, Netherlands, Japan), Germany still refusing, its law calls them lifestyle drugs.
Food and drink revenue lost to Ozempic-class drugs by 2030: $50 billion a year in the US alone.
Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound are the biggest weight-loss drugs in history. All 4 are peptides that copy gut hormones, GLP-1, and for Mounjaro and Zepbound a second one, GIP, which tell your brain you are full. Users lose 15 to 20% of body weight.
For 10,000 years hunger ran humans. In 2026 humans started running hunger. 2.5 billion adults are overweight or obese today. The US pill costs $149, Medicare pays $50 a month, and in India, China and Brazil the Ozempic patent died in March 2026: copies from $15 a month.
Medically it holds, with limits: 20% fewer heart attacks, strokes and cardiac deaths combined, in people who already had heart disease, the weight comes back when you stop, and Cochrane warns the sellers paid for most trials. UK regulators logged 1,176 pancreatitis reports and 18 reports with a fatal outcome on Mounjaro alone and put a fatal-pancreatitis warning on the whole class in January 2026.
A peptide is cheap to copy. That built the black market: fake Ozempic pens filled with insulin, raw semaglutide powder from Chinese labs sold as "research peptides", wellness clinics stacking it with unapproved healing peptides like BPC-157.
The healing-peptide craze, BPC-157 and the Wolverine stack, has its own card.
Between Big Pharma and AliExpress, pick the pharmacy. Not because the pharmacy is always right, but because there the side effects are written down, reported and treated. The kitchen syringe has none of that.
The sellers now call it the first longevity drug. Wall Street counts 30 million Americans by 2030. I count 100 million worldwide: 50 million in the US, 30 million in India and China on copies, 20 million across Europe, Brazil, Japan and the Gulf. The rich switch hunger off, the poor eat what the machine sells.
The pill treats the symptom. Fast food and processed food are the disease. We built a $100 billion industry to sell the antidote to the poison, and both sides bill you monthly.
